Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
130M
-
Number of holders
-
223
-
Total 13F shares, excl. options
-
103M
-
Shares change
-
+815K
-
Total reported value, excl. options
-
$6.47B
-
Value change
-
+$69M
-
Put/Call ratio
-
0.37
-
Number of buys
-
113
-
Number of sells
-
-84
-
Price
-
$62.80
Significant Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) as of Q4 2023
247 filings reported holding PCVX - Vaxcyte, Inc. - COMMON STOCK as of Q4 2023.
Vaxcyte, Inc. - COMMON STOCK (PCVX) has 223 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 103M shares
of 130M outstanding shares and own 79.34% of the company stock.
Largest 10 shareholders include FMR LLC (14.2M shares), BlackRock Inc. (8.58M shares), VANGUARD GROUP INC (8.45M shares), RA CAPITAL MANAGEMENT, L.P. (7.89M shares), JANUS HENDERSON GROUP PLC (6.98M shares), WELLINGTON MANAGEMENT GROUP LLP (4.43M shares), Capital Research Global Investors (3.44M shares), STATE STREET CORP (3.39M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.68M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.97M shares).
This table shows the top 223 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.